U.S. Markets closed

Sinovac Biotech Ltd. (SVA)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
6.470.00 (0.00%)
At close: 1:59PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.47
BidN/A x N/A
AskN/A x N/A
Day's Range6.47 - 6.47
52 Week Range6.47 - 6.47
Avg. Volume0
Market Cap460.249M
Beta (5Y Monthly)0.05
PE Ratio (TTM)6.66
EPS (TTM)0.97
Earnings DateApr 22, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
  • Reuters

    REFILE-Sinovac CEO complained about anti-China comments in Brazil -sources

    The chief executive of Sinovac Biotech Ltd, the main supplier of COVID-19 vaccines to Brazil, complained last month to Brazilian diplomats in Beijing that anti-China comments in Brasilia were not helping with delayed shipments, two people with knowledge of the matter told Reuters. Sinovac CEO Yin Weidong suggested an official retraction would make for a more "fluid" relationship between China and Brazilian President Jair Bolsonaro, the sources said. Bolsonaro, who complained during his 2018 campaign about a string of Chinese acquisitions in Brazil, said in a speech on May 5 that the coronavirus pandemic could be "chemical warfare" waged by the fastest growing nation, without naming China.

  • Reuters

    China builds new plant for IMBCAMS COVID-19 vaccine -state media

    China is building a new COVID-19 vaccine factory that is capable of boosting annual production of a shot developed by a medical research institute to between 500 million and 1 billion doses, state-backed media said on Wednesday. The vaccine, developed by the Institute of Medical Biology of the Chinese Academy of Medical Sciences (IMBCAMS), is one of seven shots approved for use in China. It was not immediately clear how many doses of the vaccine are currently produced and supplied for China's inoculation campaign.

  • Reuters

    Sinovac, Pfizer/BioNtech COVID-19 vaccines prove highly effective in Uruguay -government

    Uruguay on Tuesday released real-world data on the impact of Sinovac Biotech's COVID-19 vaccine among its population that showed it was over 90% effective in preventing intensive care admissions and deaths. The shot reduced deaths by 95% and intensive care admissions by 92%, and also showed 61% efficacy in cutting coronavirus infections, the government said. A total of 795,684 people - health workers and members of the general population between the ages of 18 and 69 - at least 14 days after receiving their second dose of Sinovac's CoronaVac were compared to unvaccinated people to determine the real-world vaccine effectiveness, the government said in a report.